TDC
IMGN

Thompson Davis & Co’s Immunogen Inc IMGN Stock Holding History

Thompson Davis & Co’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-139
Closed -$1K – 1130
2017
Q3 		$1K Sell
139
-209
-60% -$1.39K ﹤0.01% 1091
2017
Q2 		$2K Hold
348
– – ﹤0.01% 1011
2017
Q1 		$1K Hold
348
– – ﹤0.01% 1125
2016
Q4 		$1K Hold
348
– – ﹤0.01% 1098
2016
Q3 		$1K Hold
348
– – ﹤0.01% 1078
2016
Q2 		$1K Hold
348
– – ﹤0.01% 1031
2016
Q1 		$3K Hold
348
– – ﹤0.01% 908
2015
Q4 		$5K Hold
348
– – 0.01% 842
2015
Q3 		$3K Hold
348
– – ﹤0.01% 974
2015
Q2 		$5K Hold
348
– – 0.01% 921
2015
Q1 		$3K Hold
348
– – ﹤0.01% 1033
2014
Q4 		$2K Buy
+348
New +$3.18K ﹤0.01% 1112

Other funds holding IMGN

ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Thompson Davis & Co's IMGN Position: Q4 2017 in Review

Thompson Davis & Co sold out of Immunogen Inc (IMGN) in Q4 2017, closing a stake of 139 shares — an estimated $1K sold.

Thompson Davis & Co first reported a position in IMGN in Q4 2014 and held it in 12 quarters. The position peaked at $5K in Q4 2015. 200 funds tracked by Wall St. Rank hold IMGN as of Q4 2017.

  • Thompson Davis & Co reported no remaining Immunogen Inc position as of Q4 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 139 Immunogen Inc shares in Q4 2017, an estimated $1K.
  • Thompson Davis & Co first reported a position in Immunogen Inc in Q4 2014 and held it in 12 quarters.
  • Thompson Davis & Co's Immunogen Inc position peaked at $5K in Q4 2015.
  • 200 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.